SynthesisBMC infectious diseases2020
Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- GastrointestinalFrontiers in immunology · 2022Pooled it
- Review
- An Interpretable Machine Learning Model for Predicting the Presence of Talaromycosis in HIV Patients Lacking Skin Lesions.Mycopathologia · 2026Article
- Metagenomic next-generation sequencing of cerebrospinal fluid reveals pathogen spectrum and mortality predictors among patients with advanced HIV-1 disease at a tertiary hospital in China.Virology journal · 2026Article
- Epidemiology and factors associated with Talaromyces marneffei detection in the mainland of China, 2022-2024: a cross-sectional study of hospitalized patients.BMC public health · 2026Article
- Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromycosis: a multicenter retrospective study.PLoS neglected tropical diseases · 2026Article
- Comparison of talaromycosis in HIV-infected patients with and without Talaromyces marneffei bloodstream infection.BMC infectious diseases · 2026Article
- Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis.Microorganisms · 2026Review
- STAT1-L351F is associated with enhanced interferon signaling and susceptibility toFrontiers in immunology · 2026Article
- Clinical Features and Diagnostic Challenges ofInfection and drug resistance · 2026Article
- Environmental transmission from bamboo rats: Mapping current and future talaromycosis risk in China under climate change.One health (Amsterdam, Netherlands) · 2025Article
- Pulmonary talaromycosis leads to respiratory failure in an HIV-negative patient in Shandong Province: case report.BMC infectious diseases · 2025Article
- Disseminated Talaromyces marneffei infection presenting as pulmonary cavitary nodules: a case report.BMC infectious diseases · 2025Article
- Prognostic model of HIV-associated talaromycosis in south China: A large-scale retrospective study.PLoS neglected tropical diseases · 2025Article
- PANoptosis-mediated mechanisms underlying AST elevation in Talaromyces marneffei infection.PLoS neglected tropical diseases · 2025Article
- Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.PLoS neglected tropical diseases · 2025Article
- Multicenter Case-Control Study of Behavioral, Environmental, and Geographic Risk Factors for Talaromycosis, Vietnam.Emerging infectious diseases · 2025Article
- Two cases of Talaromyces marneffei tracheobronchial infection in HIV-negative patients.BMC infectious diseases · 2025Article
- Clinical Features of Invasive Fungal Disease in China Tertiary Hospital: A Prospective, Multicenter Study.Mycopathologia · 2025Article
- Integration of Transcriptomics and Proteomics to Elucidate Inhibitory Effect and Mechanism of Antifungalmycin B from MarineMarine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTalaromyces marneffei (TM) is a dimorphic fungus mainly prevalent in Southeast Asian countries, which often causes disseminated life-threatening infection. TM infection often occurs in HIV/AIDS patients even in the antiretroviral therapy (ART) era. However, there has as yet, not been a systematic analysis of the prevalence of TM infection in HIV-infected populations in Asia.
methodsIn this study, we searched Pubmed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and WanFang from inception to 21 November 2018 for studies reporting TM infection in people living with HIV/AIDS (PLWHA). Our meta-analysis included studies investigating the prevalence of TM infection in PLWHA. Reviews, duplicate studies, and animal studies were excluded. A random effects model was used to estimate pooled prevalence, and meta-regression analysis was conducted to explore potential factors for heterogeneity.
results159,064 patients with HIV infection in 33 eligible studies were included in our meta-analysis. The pooled prevalence of TM infection in PLWHA was 3.6%. Vietnam had the highest prevalence (6.4%), followed by Thailand (3.9%), China (3.3%), India (3.2%) and Malaysia (2.1%). In China, TM infection was most prevalent in South China (15.0%), while the burden in Southwest China was not very heavy (0.3%). CD4+ T-cell counts below 200 cells/mm
conclusionsThe burden of TM infection in Asia is heavy, and varies from region to region. PLWHA in lower latitude areas are more likely to suffer from TM infection. Optimization of diagnostic tools and universal screening for TM in vulnerable people to ensure early case detection and prompt antifungal treatment should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.